While at CRA, Michael led engagements in therapeutic area strategy, asset strategy, pricing and market access, mergers and acquisitions, and corporate strategy, primarily in oncology, rare disease, and immunology. Prior to his role at CRA, he co-founded SynActive Biosciences, which focused on stem cell-derived neuron technologies. Previously, he was a Program Manager in the Biosciences Division at the Department of Defense where he researched emerging pathogens and bio-terrorism threat agents. He has written many publications on genomics and has presented his research at academic conferences. He is conversant in both German and Spanish.
Michael attended The University of Wisconsin-Madison where he recieved a B.S. in Bacteriology and his PhD in Genetics. Additionally, Michael received his MBA from The University of Chicago Booth School of Business.